US2007178077A1PendingUtilityA1
Method for in vitro preconditioning of myoblasts before transplantation
Est. expiryOct 18, 2016(expired)· nominal 20-yr term from priority
Inventors:Jacques P. Tremblay
C12N 2501/70A61K 35/12C12N 2502/1323C12N 2501/01C12N 2510/00A61K 48/00A61K 38/00C12N 2501/59C12N 5/0658C12N 2501/115
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods of pretreating healthy donor's myoblast cultures with growth or trophic factors on transplantation into subjects suffering from myopathic conditions such as muscular dystrophy. Compositions comprising myoblasts and fusion-promoting metalloproteases can be transplanted. Alternatively, myoblasts can be transplanted along with an agent inducing the expression of a fusion-promoting metalloprotease, or a composition comprising genetically-modified myoblasts capable of expressing a fusion-promoting metalloprotease can be transplanted.
Claims
exact text as granted — not AI-modified1 . A method for increasing the number of transplanted myoblasts which migrate into a recipient muscle tissue and which fuse either with the myoblasts or muscle fibers of said recipient muscle tissue, said method comprising transplanting into a patient affected by a recessive myopathy a composition comprising myoblasts transformed with a gene construct capable of expressing a metalloprotease involved in extracellular matrix destruction.
2 . The method of claim 1 , wherein the metalloprotease is Gelatinase A, Matrilysine, or both.
3 . The method of claim 1 , wherein the expression of said metalloprotease is inducible.
4 . The method of claim 1 , wherein said myoblasts to be transplanted are grown in vitro in a culture medium, suitable for growth of myoblasts, which comprises a growth or trophic factor.
5 . The method of claim 4 , wherein said growth or trophic factor is basic fibroblast growth factor.
6 . The method of claim 1 , wherein the recessive myopathy affecting said patient is Duchenne muscular dystrophy.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.